Európai Unió - angol - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h7n1 subtype (strain, a/ck/italy/473/99) - immunologicals for aves - chicken; ducks - for active immunisation of chickens and ducks against avian influenza type a, subtype h7n1.efficacy has been evaluated on the basis of preliminary results in chickens and ringed teals.in chickens, reduction of clinical signs, mortality, excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.in ducks, reduction of excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.although it has not been investigated with this particular ai vaccine strain, studies performed with other strains show that protective levels of serum antibody titres would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine. the duration of immunity in ducks is unknown.

Egyesült Államok - angol - NLM (National Library of Medicine)

energique, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 200 [hp_c] in 1 ml - to be used according to standard homeopathic indications.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. to be used according to standard homeopathic indications.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

Egyesült Államok - angol - NLM (National Library of Medicine)

deseret biologicals, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Egyesült Államok - angol - NLM (National Library of Medicine)

deseret biologicals, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, swollen glands, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, swollen glands, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Egyesült Államok - angol - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (formaldehyde inactivated) (unii: q3p251c5mt) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:ld80h821hf), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (formaldehyde inactivated) (unii: kmo6tk08j4) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:w929z18nv6), influenza b virus b/ - fluad is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine. fluad is approved for use in persons 65 years of age and older. approval is based on the immune response elicited by fluad. data demonstrating a decrease in influenza disease after vaccination with fluad are not available. [see clinical studies (14)] do not administer fluad to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad is not approved for use in persons <65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad in pregnancy. a developmental toxicity study has been performed in female rabbits administered fluad prior to mating and during gestation. a 0.5 ml dose was injected on each occasion (a single human dose i

Egyesült Államok - angol - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (formaldehyde inactivated) (unii: xw4jb03ti5) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:92xe6ghc89), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (formaldehyde inactivated) (unii: 3nzw5nd3d6) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:k329ycd1n9), influenza b virus b/maryland/15/2016 antigen (formaldehyde inact - fluad is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine. fluad is approved for use in persons 65 years of age and older. approval is based on the immune response elicited by fluad. data demonstrating a decrease in influenza disease after vaccination with fluad are not available. [see clinical studies (14)] do not administer fluad to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad in pregnancy. a developmental toxicity study has been performed in female rabbits administered fluad prior to mating and during gestation. a 0.5 ml dose was injected on each occasion (a single human dose

Egyesült Államok - angol - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) antigen (formaldehyde inactivated) (unii: 2j002y0b0w) (influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:mz5g0f0san), influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) antigen (formaldehyde inactivated) (unii: p8orn3uom6) (influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:thg3pu0kok), influenza b virus b/victoria/705/2018 bvr-11 - fluad is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine. fluad is approved for use in persons 65 years of age and older. this indication is approved under accelerated approval based on the immune response elicited by fluad [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. do not administer fluad to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad in pregnancy. a developmental toxicity study has been performed in female rabbits administered fluad prior to mating and du

Egyesült Államok - angol - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) antigen (formaldehyde inactivated) (unii: 2j002y0b0w) (influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:mz5g0f0san), influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) antigen (formaldehyde inactivated) (unii: p8orn3uom6) (influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:thg3pu0kok), influenza b virus b/victoria/705/2018 bvr-11 - fluad quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. fluad quadrivalent is approved for use in persons 65 years of age and older. this indication is approved under accelerated approval based on the immune response elicited by fluad quadrivalent [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. do not administer fluad quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad quadrivalent is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad quadrivalent in pregnancy. there were no development

Egyesült Államok - angol - NLM (National Library of Medicine)

maierto inc - bovine tuberculin (unii: hkd62g79n5) (bovine tuberculin - unii:hkd62g79n5), aconitum napellus whole (unii: u0nq8555jd) (aconitum napellus whole - unii:u0nq8555jd), cryptolepis sanguinolenta whole (unii: 9q3jwj3gxg) (cryptolepis sanguinolenta whole - unii:9q3jwj3gxg), cairina moschata heart/liver autolysate (unii: rn2hc612gy) (cairina moschata heart/liver autolysate - unii:rn2hc612gy), influenza a virus a/hong kong/2671/2019 (h3n2) nib-121 neuraminidase antigen (uv, formaldehyde inactivated) (unii: 2828w - anas barbariae 30ch hpus ..... reduces the duration of and severity of flu-like symptoms bacillinum 30ch hpus ….. helps in treatment of tuberculosis and relief from other respiratory disorders like asthma and bronchitis pyrogenium 30ch hpus ….. helps promote and maintain a healthy upper respiratory tract, and temporarily alleviates symptoms associated with general nasal and sinus congestion. sambucus nigra 30ch hpus ….. boosts immune system, and helps prevent and ease cold and flu-like symptoms eupatorium perfoliatum 30ch hpus ….. helps to reduce fever, and relieves stiffness and bone pain influenzinum 30ch hpus …. prevention and relief of flu-like symptoms arsenicum album 30ch hpus ….. reduces inflammation in body aconitum napellus 30ch hpus ….. alleviates fever and chills cryptolepis sanguinolenta 30ch hpus ….. antibacterial and anti-inflammatory activity uses* temporarily relieves upper respiratory, covid like symptoms. *these “uses” have not been evaluated by the food and drug administration.

Egyesült Államok - angol - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (formaldehyde inactivated) (unii: wd5e5vym2e) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:erb9sj9vmq), influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) antigen (formaldehyde inactivated) (unii: yy2tbu8yqs) ( iinfluenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:33qej7v9bf), influenza b virus b/victoria/705/201 - fluad quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. fluad quadrivalent is approved for use in persons 65 years of age and older. this indication is approved under accelerated approval based on the immune response elicited by fluad quadrivalent [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. do not administer fluad quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad quadrivalent is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad quadrivalent in pregnancy. there were no development